BFS
EWTX icon

Bare Financial Services’s Edgewise Therapeutics EWTX Stock Holding History

Bare Financial Services’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$731 Hold
18
– – ﹤0.01% 1511
2026
Q1 		$567 Hold
18
– – ﹤0.01% 1462
2025
Q4 		$447 Buy
+18
New +$361 ﹤0.01% 1476

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bare Financial Services's EWTX Position: Q2 2026 in Review

Bare Financial Services held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 18 shares worth $731. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Bare Financial Services first reported a position in EWTX in Q4 2025 and has held it in 3 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Bare Financial Services held 18 shares of Edgewise Therapeutics worth $731 as of Q2 2026.
  • Bare Financial Services left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1511 holding.
  • Bare Financial Services first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.